Mesolimbic pathway
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
The mesolimbic pathway is one of the neural pathways in the brain that links the ventral tegmentum in the midbrain to the nucleus accumbens, which is located in the striatum and is a part of the limbic system. It is one of the four major pathways where the neurotransmitter dopamine is found.
Function
The mesolimbic pathway is thought to be involved in producing pleasurable feeling, and is often associated with feelings of reward and desire, particularly because of the connection to the nucleus accumbens, which is also associated with these states. Because of this, this pathway is heavily implicated in neurobiological theories of addiction. However, recent research has pointed towards this pathway being involved in incentive salience rather than euphoric mood states.
Clinical significance
The mesolimbic pathway is one of the major pathways targeted by antipsychotic medication. Although the process is not fully understood, it has been found that disruption of dopamine function (particularly, an excess of dopamine) in this area has been linked to psychosis and the 'positive symptoms' of schizophrenia (particularly delusions and hallucinations). Successful antipsychotic medication is therefore thought to have its effect by blocking dopamine receptors in this pathway.
Dopamine neurons are lost in the mesolimbic pathway in Parkinson's Disease; however, they are lost far more quickly in the nigrostriatal pathway, and, because deficits do not become apparent until a reduction of 80-90% in the numbers of neurons, their loss here is asymptomatic.
Other pathways
Other major dopamine pathways include:
See also
External links
- Diagram at utah.edu
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
